Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL SurveillanceLars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
17 March 2023
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registriesBente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindström
22 February 2023
Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task forceEve Mary Dorothy Smith, Amita Aggarwal, Jenny Ainsworth, Eslam Al-Abadi, Tadej Avcin, Lynette Bortey, Jon Burnham, Coziana Ciurtin, Christian M Hedrich, Sylvia Kamphuis, Deborah M Levy, Laura B Lewandowski, Naomi Maxwell, Eric F Morand, Seza OzenSee the full list of authors
10 January 2023
Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseasesNaomi J Patel, Claire Cook, Kathleen Vanni, Xiaoqing Fu, Xiaosong Wang, Yumeko Kawano, Grace Qian, Buuthien Hang, Shruthi Srivatsan, Emily P Banasiak, Emily Kowalski, Katarina Bade, Yuqing Zhang, Jeffrey A Sparks, Zachary S. Wallace
28 November 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritisDaniel H Solomon, Jon T Giles, Katherine P Liao, Paul M Ridker, Pamela M Rist, Robert J Glynn, Rachel Broderick, Fengxin Lu, Meredith T Murray, Kathleen Vanni, Leah M Santacroce, Shady Abohashem, Philip M Robson, Zahi Fayad, Venkatesh ManiSee the full list of authors
30 November 2022
Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysisSébastien Sanges, Lisa Rice, Ly Tu, Eleanor Valenzi, Jean-Luc Cracowski, David Montani, Julio C Mantero, Camille Ternynck, Guillemette Marot, Andreea M Bujor, Eric Hachulla, David Launay, Marc Humbert, Christophe Guignabert, Robert Lafyatis
5 December 2022
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, Kim Lauper, Denis Mongin, Florenzo Iannone, Karel Pavelka, Dan C Nordström, Nevsun Inanc, Catalin Codreanu, Kimme L Hyrich, Denis Choquette, Anja Strangfeld, Burkhard F Leeb, Ziga RotarSee the full list of authors
13 September 2022
Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal studyRobert B M Landewé, Denis Poddubnyy, Proton Rahman, Filip E Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R Lisse, So Young Park, Lianne Gensler
13 September 2022
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron waveYumeko Kawano, Naomi J Patel, Xiaosong Wang, Claire E Cook, Kathleen MM Vanni, Emily N Kowalski, Emily P Banasiak, Grace Qian, Michael DiIorio, Tiffany Y-T Hsu, Michael E Weinblatt, Derrick J Todd, Zachary S Wallace, Jeffrey A Sparks
9 August 2022
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ONYannick Allanore, Madelon C Vonk, Oliver Distler, Arata Azuma, Maureen D Mayes, Martina Gahlemann, Alexandra James, Veronika Kohlbrenner, Margarida Alves, Dinesh Khanna, Kristin B Highland,
16 August 2022